INTRODUCTION
============

*Streptococcus agalactiae* (group B β-hemolytic streptococci) can cause several invasive infections, including sepsis, infective endocarditis, septic arthritis, and meningitis, especially in neonates and the elderly \[[@b1-alm-2020-40-5-370], [@b2-alm-2020-40-5-370]\]. *S. agalactiae* infections are classified as invasive (blood, cerebrospinal fluid, joint fluid, pleural effusion, ascites, and closed pus) or non-invasive (urine and vaginal discharge) \[[@b3-alm-2020-40-5-370]\]. Multilocus sequence typing (MLST) for sequence type (ST) determination has been used to evaluate the clonal distribution or persistence of *S. agalactiae* from urine and vagina \[[@b3-alm-2020-40-5-370]\].

*S. agalactiae* possesses numerous virulence factors, including capsular polysaccharide (CPS), alpha and beta antigens of the surface-associated C protein, and the surface protein Rib. CPS is the most important virulence factor and is used for strain typing \[[@b4-alm-2020-40-5-370]\]. Alpha antigen of the surface-associated C protein (encoding gene *bca*) mediates adherence to the epithelium, whereas beta antigen of the surface-associated C protein (encoding gene *bac*) is involved in invasiveness and resistance to phagocytic clearance \[[@b5-alm-2020-40-5-370], [@b6-alm-2020-40-5-370]\]. Protein Rib (encoding gene *rib*), which exhibits resistance to proteases, confers protective immunity and is detected in most CPS III isolates, which cause severe infections in neonates \[[@b5-alm-2020-40-5-370]\]. *lmb* and *cylE* encode human laminin binding protein and beta-hemolysin, respectively.

There are two major phenotypes of macrolide resistance in streptococci: an MLS~B~ phenotype is resistant to macrolides, lincosamides, and streptogramin B, and an M phenotype is resistant to macrolides, but not to lincosamides and streptogramin B \[[@b7-alm-2020-40-5-370]\]. The MLS~B~ phenotype in streptococci can result from induced/constitutive expression of the antimicrobial resistance (AMR) determinants, *erm*(A) and *erm*(B), whereas the M phenotype can be caused by the *mef*(A) determinant \[[@b7-alm-2020-40-5-370]\]. In addition, an L phenotype exists, which is resistant to lincosamides, but not to macrolides \[[@b8-alm-2020-40-5-370]\]. The clindamycin-resistant erythromycin-susceptible (CRES) phenotype corresponds to the L phenotype \[[@b9-alm-2020-40-5-370]\].

The CRES phenotype (L phenotype) is rare in *S. agalactiae*. It has been described in clinical isolates from Korea and is caused by antimicrobial modification mediated by *lnu*(B) \[[@b10-alm-2020-40-5-370]\]. Members of the *lnu* gene family encode nucleotidyl transferase enzymes that catalyze the adenylation of lincomycin and clindamycin. The CRES phenotype is also mediated by two genes of the *lsa* gene family, namely *lsa*(C) and *lsa*(E), which encode ATP-binding proteins that have been classified as class 2 ATP-binding cassette transporters (antibiotics efflux pumps) \[[@b11-alm-2020-40-5-370]\]. While the overall frequency of this phenotype in *S. agalactiae* was quite low (65/21,186=0.31%), it had increased in 2014--2015 in the USA \[[@b11-alm-2020-40-5-370]\].

We aimed to determine the genetic characteristics of CRES *S. agalactiae* in Korea based on whole genome sequencing (WGS). To the best of our knowledge, this is the first report on WGS-based characteristics of *S. agalactiae* in Korea.

MATERIALS AND METHODS
=====================

Study design
------------

*S. agalactiae* isolates collected between 2010 and 2017 were randomly selected from the repository at Gyeongsang National University Hospital (GNUH) in Gyeongnam Province, Korea. We included a total of 66 isolates: invasive isolates from blood (N=26) and cerebrospinal fluid (CSF) (N=10) as well as non-invasive isolates from urine (N=17) and vaginal discharge (N=13); repeated isolates from the same patients were excluded. Bacterial identification was conducted using a Vitek-2 automated identification system (bioMerieux Inc., Marcy l'Etoile, France). All isolates were stored at −70°C to −80°C before being processed for further evaluation.

Patients' sex and age were obtained from the electronic medical records. In total, 66 patients with a median age of 50.5 years (range, 0--86 years), including 12 children, 54 adults, and 32 males (48.5%), were enrolled. The study protocol was approved by the Institutional Review Board of GNUH (approval number: GNUH 2016-03-010). Informed consent was waived because of the retrospective nature of the study.

Antimicrobial susceptibility testing (AST)
------------------------------------------

AST was conducted using 11 antimicrobial agents, including β-lactam, tetracycline, macrolide/lincosamide (ML), and fluoroquinolone, to evaluate AMR levels by the broth microdilution method using a Vitek-2 System and an ST-01 test kit (bioMerieux Inc.). CRES *S. agalactiae* was defined as having a minimum inhibitory concentration of \>1 μg/mL for clindamycin and of \<0.25 μg/mL for erythromycin. Seven isolates showed the CRES phenotype. We also included seven isolates showing the clindamycin-susceptible erythromycin-resistant (CSER) phenotype for comparison. In addition, we included 13 isolates that were clindamycin-resistant erythromycin-resistant, and 29 isolates that were clindamycin-susceptible erythromycin-susceptible. The seven CRES isolates were recovered from urine (N=5) and vaginal discharge (N=2) during a limited period (March 2010 to August 2011).

Bacterial identification and AST had been performed previously by routine microbiological procedures, whereas WGS and bioinformatics analysis had been conducted for this study.

WGS
---

*S. agalactiae* isolates were grown at 35°C in Todd-Hewitt broth (Becton Dickinson, Sparks, MD, USA) for 16--18 hours. Genomic DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany) after pretreatment with lysozyme (Thermo Fisher Scientific, Waltham, MA, USA) and proteinase K (Qiagen) \[[@b12-alm-2020-40-5-370]\]. *S. agalactiae* isolates were identified by 16S rRNA gene sequencing with amplifying/sequencing primer set (27F: AGAGTTTGATCMTGGCTCAG and 1485R: TACGGTTACCTTGTTACGAC) developed in-house using an ABI 3730 DNA sequencing instrument (Applied Biosystems, Foster City, CA, USA). The sequencing library was prepared using a TruSeq DNA LT Sample Prep Kit (Illumina, San Diego, CA, USA) for the Illumina MiSeq system. Draft genome sequences of the isolates were determined based on 300-bp paired-end reads. Illumina sequencing data were assembled using SPAdes 3.13.0 (Algorithmic Biology Lab, St. Petersburg Academic University of the Russian Academy of Sciences). For gene-finding and functional annotation, we used the whole genome analysis pipeline of ChunLab (Seoul, Korea). Protein-coding DNA sequences were predicted using Prodigal 2.6.2 (<https://github.com/hyattpd/Prodigal>) \[[@b13-alm-2020-40-5-370]\].

AMR genotyping
--------------

AMR genotyping was conducted based on the contig sequences obtained using ResFinder version 3.2 (<https://cge.cbs.dtu.dk/services/ResFinder/>) managed by the Center for Genomic Epidemiology \[[@b14-alm-2020-40-5-370]\]. This tool can detect genes conferring resistance to β-lactams, macrolide, lincosamide, tetracycline, quinolone, oxazolidinone, sulfonamide/trimethoprim, glycopeptide, aminoglycoside, phenicol, fosfomycin, nitroimidazole, rifampicin, fusidic acid, and colistin. AMR genotypes were determined based on an identity threshold \>90% and a minimum length of 60% as compared with the reference sequence in the database.

MLST
----

MLST (allelic profile: *adhP--pheS--atr--glnA--sdhA--glcK--tkt*) was conducted based on the contig sequences using the MLST server (<https://cge.cbs.dtu.dk/services/MLST/>) managed by the Center for Genomic Epidemiology \[[@b15-alm-2020-40-5-370]\]. The STs were grouped into clonal complexes (CCs), whereby related STs were classified as single-locus variants differing in only one housekeeping gene. An expansion of the goeBURST algorithm implemented in PHYLOViZ (<http://www.phyloviz.net/>) was used to produce a minimum-spanning tree representing possible relationships among the STs \[[@b16-alm-2020-40-5-370]\].

CPS genotyping
--------------

CPS genotyping and detection of the *S. agalactiae*-specific *dltS* gene were conducted based on the contig sequences by PCR simulation \[[@b17-alm-2020-40-5-370]\] in the online application, Serial Cloner (<http://serialbasics.free.fr/Serial_Cloner.html>). The CPS genotypes included Ia, Ib, II, III, IV, V, VI, VII, and VIII.

Virulence gene profiling
------------------------

The presence of five virulence genes (*bca-rib-bac-lmb-cylE*) was determined based on the contig sequences by PCR simulation in Serial Cloner \[[@b18-alm-2020-40-5-370]--[@b20-alm-2020-40-5-370]\]. Sequence identity of the virulence genes in all simulation PCR-positive strains was confirmed using the basic local alignment search tool (BLAST) (<http://blast.ddbj.nig.ac.jp/blastn?lang=ja>).

Phylogenetic tree analysis
--------------------------

A phylogenetic tree was constructed using Orthologous Average Nucleotide Identity Tool, which measures similarity among multiple genome sequences based on the OrthoANI algorithm and BLAST calculations, on EZBioCloud (<https://www.ezbiocloud.net/tools/orthoani>) \[[@b21-alm-2020-40-5-370]\].

Statistical analysis
--------------------

We used Fisher's exact probability tests (two-sided) to determine significant differences between CRES and CSER isolates using SPSS Statistics version 22.0 (IBM Corp., Armonk, NY, USA). *P*\<0.05 indicated statistical significance.

RESULTS
=======

We deposited the draft genome sequences of the 66 *S. agalactiae* isolates into the National Center for Biotechnology Information (NCBI) database ([Table 1](#t1-alm-2020-40-5-370){ref-type="table"}). The WGS of the *S. agalactiae* isolate NCTC8181 (accession number UAVB00000000) obtained from environmental milk was used as a reference genome. The number of contigs ranged from eight (for isolate GCH73) to 90 (for isolate GCH63).

The goeBURST diagram is shown in [Fig. 1](#f1-alm-2020-40-5-370){ref-type="fig"}. All seven CRES isolates belonged to ST19 (CC19), suggesting a clonal distribution of the CRES isolates ([Table 2](#t2-alm-2020-40-5-370){ref-type="table"}), whereas the seven CSER isolates belonged to ST19 (CC19) (N=3), ST2/ST1 (CC2) (N=2), or ST23 (N=2).

All CRES isolates showed the *lnu*(B)-*lsa*(E) ML resistance genotype ([Table 2](#t2-alm-2020-40-5-370){ref-type="table"}). However, none of the CSER isolates possessed the *lnu*(B)-*lsa*(E) genotype (*P*=0.001). All CRES isolates showed the *aac*(6′)-*aph*(2″) aminoglycoside resistance genotype, whereas none of the CSER isolates did. All isolates did not show AMR genes for β-lactams, quinolone, oxazolidinone, sulfonamide/trimethoprim, glycopeptide, phenicol (except for *cat*\[pC194\] in isolate GCH2), fosfomycin, nitroimidazole, rifampicin, fusidic acid, and colistin.

All isolates possessed the *dltS* gene specific to *S. agalactiae*, validating species identification. All CRES isolates were CPS III, whereas the CSER isolates possessed diverse CPS types ([Table 2](#t2-alm-2020-40-5-370){ref-type="table"}).

All CRES isolates exhibited the *rib-lmb-cylE* profile ([Table 2](#t2-alm-2020-40-5-370){ref-type="table"}). The CSER isolates had a diverse virulence gene profile. There was a significant difference in the frequency of *lnu*(B)-*lsa*(E) or *lsa*(C) between invasive (N=6/36, 16.7%) and non-invasive (N=13/30, 43.3%, *P*=0.017) isolates. There was no difference in the frequency of *lnu*(B)-*lsa*(E) or *lsa*(C) between urine (N=9/17, 52.9%) and vaginal discharge (N=4/13, 30.8%, *P*=0.200).

The phylogenetic tree revealed that all CRES isolates belonged to the same group, whereas CSER isolates belonged to diverse groups, corroborating the clonal distribution of the CRES isolates ([Fig. 2](#f2-alm-2020-40-5-370){ref-type="fig"}). The group distribution on the tree was in accordance with the CPS genotype distribution (e.g., Ia, Ib, III, V, and VIII).

The *erm*(B) sequence of the CRES isolate GCH61 in our study was compared with the previously registered sequence (738 bp) of *S. agalactiae* isolate KMP104 (RefSeq accession number DQ355148). This sequence (accession number LC512876) contained C222T (N74N), T224C (I75T), and A299G (N100S) nucleotide (amino acid) substitutions in addition to the insertion of an IS*1216E* element at nucleotide position 642, which resulted in the deletion of a segment spanning nucleotides 642--738 (97 bp) ([Fig. 3](#f3-alm-2020-40-5-370){ref-type="fig"}).

DISCUSSION
==========

Our study revealed that CRES isolates have unique features compared with CSER isolates, including their AMR genotype \[*lnu*(B)-*lsa*(E) with *aac*(6′)-*aph*(2″)\], ST19/CC19, CPS type III, virulence gene profile of *rib-lmb-cylE*, and in terms of cluster on the phylogenetic tree.

We searched for the presence of CRES *S. agalactiae* isolates in the Isolates Database on the MLST website (<https://pubmlst.org/bigsdb?db=pubmlst_sagalactiae_isolates&page=query>). Interestingly, only one CRES isolate was previously recovered from a 61-year-old female patient with bacteremia in Kangwon Province in the north of Korea in 2010 \[[@b22-alm-2020-40-5-370]\]. Another CRES isolate of CPS genotype III was isolated from a patient with bacteremia in Bergen, Norway, in 2010 \[[@b23-alm-2020-40-5-370]\]. Three CRES isolates of serotype III were recovered from clinical specimens in Seoul during 2010--2013 \[[@b9-alm-2020-40-5-370], [@b24-alm-2020-40-5-370]\]. These findings are in line with our observation that all CRES isolates in Gyeongnam Province in the south of Korea were recovered between March 2010 and August 2011. Thus, the CRES isolates appeared to be epidemic in Korea and other countries during this limited period.

In line with a previous study \[[@b11-alm-2020-40-5-370]\], we found a significant difference in the distribution of AMR genotype of *lnu*(B)-*lsa*(E) between the CRES and CSER isolates. For all CRES isolates, the *lnu*(B) locus was adjacent to the *lsa*(E) locus within the same contigs, with a short 53-bp distance between these two loci. Therefore, in our study, the *lnu*(B)-*lsa*(E) gene combination seems to mainly contribute to the CRES phenotype. Further observation of the dynamic changes in the CRES phenotype and the corresponding gene transfer is needed.

The *erm*(B) confers constitutive resistance (cMLS~B~) through a conformational change in 23S ribosomal RNA methyltransferase \[[@b8-alm-2020-40-5-370]\]. Deletion of a segment in *erm*(B) sequence in CRES suggests loss of function of the *erm*(B) protein in this isolate, resulting in an erythromycin-susceptible phenotype. Interestingly, three CRES isolates (NUBL-9601, NUBL-9602, and NUBL-9603) isolated at a hospital in Seoul during 2010--2013 had the identical sequences (accession numbers LC430933, LC430934, and LC430935) (3) \[[@b9-alm-2020-40-5-370], [@b10-alm-2020-40-5-370]\]. Furthermore, we observed the IS*1216E* insertion in *erm*(B) (accession numbers LC512881, LC512882, LC512883, LC512885, and LC512886) in five isolates (GCH16, GCH19, GCH38, GCH55, and GCH58, respectively) of this study. Thus, IS*1216E* seems to be common among CRES isolates in Korea.

Four CRES isolates (GCH63, GCH64, GCH65, and GCH67) in our study possessed truncated variant sequences of *erm*(B) (624 and 678 bps) due to insertion of a TAA stop codon into the open reading frame (accession numbers LC512877, LC512878, LC512879, and LC512880), suggesting that an immature *erm*(B) protein leads to the erythromycin-susceptible phenotype. Three other phenotypes (GCH50, GCH72, and GCH78) also had truncated variant sequences (660, 678, and 510 bps, respectively) (accession numbers LC512884, LC512887, and LC512888, respectively) harboring the erythromycin-susceptible phenotype. Therefore, we may explain the mechanism of the presence of *erm*(B)-gene with the erythromycin-susceptible phenotype in CRES *S. agalactiae*.

This study has several limitations. First, clinical data, such as antibiotic treatment, outcome, and complications, does not suffice to demonstrate the relationship with the AMR genotype or virulence gene profile. Second, we cannot explain why the clonal outbreak occurred only during a limited period and is absent nowadays. Third, we did not determine translational activities and enzymatic functions of the IS*1216E* insertion-*erm*(B) and the truncated variant sequences.

In conclusion, CRES isolates were obtained during a limited period (2010--2011) and showed a genetic cluster having ST19 and CPS III in Korea as revealed by WGS. This rare AMR phenotype should be meticulously monitored, and the therapeutic efficacy of optimal antibiotics should be further evaluated.
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![goeBURST diagram of the relationships among STs of 66 *S. agalactiae* isolates. The numbers in the circles indicate the STs, and the numbers near the lines indicate the number of differing alleles between the two connected STs. Putative CCs are identified by an outer dotted frame and correspond to the STs with the highest number of single locus variants.\
Abbreviations: CC, clonal complex; ST, sequence type.](alm-2020-40-5-370f1){#f1-alm-2020-40-5-370}

![Phylogenetic tree of 66 *S. agalactiae* isolates. The phylogenetic tree was constructed using OAT, based on the OrthoANI algorithm, with *S. agalactiae* strain NCTC8181 (accession number UAVB00000000) as a reference. Asterisks (\*) indicate CRES isolates, daggers (†) indicate CSER isolates. There was a concordance of the group distribution on the tree with the CPS genotype distribution (Ia, Ib, III, V, and VIII).\
Abbreviations: CPS, capsular polysaccharide; CRES, clindamycin-resistant erythromycin-susceptible; CSER, clindamycin-susceptible erythromycin-resistant; CRER, clindamycin-resistant erythromycin-resistant; CSES, clindamycin-susceptible erythromycin-susceptible; CSEI, clindamycin-susceptible erythromycin-intermediate; CREI, clindamycin-resistant erythromycin-intermediate; CIES, clindamycin-intermediate erythromycin-susceptible; OAT, Orthologous Average Nucleotide Identity Tool.](alm-2020-40-5-370f2){#f2-alm-2020-40-5-370}

![Comparison of sequences of GCH61, NUBL-9601, and KMP104. Sequence of *erm*(B) from isolate GCH61 (accession number VYRN00000000) with the CRES phenotype contained C222T (N74N), T224C (I75T), and A299G (N100S) nucleotide (amino acid) substitutions, in addition to the insertion of an IS*1216E* element at nucleotide position 642, which resulted in the deletion of a segment spanning nucleotides 642--738 (97 bp). This sequence was identical to that from the CRES isolate NUBL-9601 (accession number LC430933). The sequence of *erm*(B) from the isolate KMP104 was used as a reference (RefSeq accession number DQ355148).\
Abbreviation: CRES, clindamycin-resistant erythromycin-susceptible.](alm-2020-40-5-370f3){#f3-alm-2020-40-5-370}

###### 

Specimen, date of collection, and accession numbers of draft genome sequences of 66 isolates of *Streptococcus agalactiae*

  Strain   Specimen            Date of specimen collection (yr/month)   Sex   Age (yr)   Accession numbers
  -------- ------------------- ---------------------------------------- ----- ---------- -------------------
  GCH2     Blood               2016/03                                  M     75         WHUI00000000
  GCH4     Blood               2016/05                                  F     83         WHUJ00000000
  GCH5     Blood               2016/06                                  F     78         WHUK00000000
  GCH7     Blood               2016/07                                  M     74         WHUL00000000
  GCH8     Blood               2016/07                                  M     79         WACQ00000000
  GCH9     Blood               2016/07                                  M     0          VYJX00000000
  GCH10    Blood               2016/08                                  F     72         VYJI00000000
  GCH11    Blood               2016/08                                  M     40         VYJJ00000000
  GCH13    Blood               2016/10                                  M     64         VYJK00000000
  GCH14    Blood               2016/12                                  M     67         VYJL00000000
  GCH15    Blood               2016/12                                  M     76         VYJM00000000
  GCH16    Blood               2017/01                                  M     43         VYJN00000000
  GCH18    Blood               2017/02                                  M     77         VYJO00000000
  GCH19    Blood               2017/02                                  M     60         VYJP00000000
  GCH21    Blood               2017/03                                  F     85         VYJQ00000000
  GCH22    Blood               2017/05                                  M     46         VYJR00000000
  GCH25    Blood               2017/06                                  M     64         VYJS00000000
  GCH26    Blood               2017/07                                  M     86         VYJT00000000
  GCH28    Blood               2017/08                                  M     54         VYJU00000000
  GCH29    Blood               2017/10                                  M     0          VYJV00000000
  GCH30    Blood               2017/10                                  F     74         VYJW00000000
  GCH32    Blood               2017/12                                  M     51         VYQL00000000
  GCH33    Blood               2016/08                                  F     56         VYQM00000000
  GCH34    Blood               2016/11                                  F     73         VYQN00000000
  GCH35    Blood               2017/05                                  M     84         VYQO00000000
  GCH36    Blood               2017/07                                  F     73         VYQP00000000
  GCH37    CSF                 2014/07                                  M     51         VYQQ00000000
  GCH38    CSF                 2014/10                                  M     0          VYQR00000000
  GCH39    CSF                 2014/12                                  M     0          VYQS00000000
  GCH40    CSF                 2015/08                                  F     0          VYQT00000000
  GCH41    CSF                 2015/08                                  F     0          VYQU00000000
  GCH42    CSF                 2016/06                                  M     50         VYQV00000000
  GCH43    Urine               2017/02                                  M     32         VYQW00000000
  GCH44    Urine               2017/02                                  F     56         VYQX00000000
  GCH45    Urine               2017/05                                  F     84         VYQY00000000
  GCH46    Urine               2017/07                                  M     61         VYQZ00000000
  GCH47    Urine               2017/07                                  F     34         VYRA00000000
  GCH48    Urine               2017/08                                  F     73         VYRB00000000
  GCH49    Urine               2017/08                                  M     65         VYRC00000000
  GCH50    Urine               2017/11                                  F     13         VYRD00000000
  GCH51    Urine               2017/12                                  M     53         VYRE00000000
  GCH53    Vaginal discharge   2016/04                                  F     34         VYRF00000000
  GCH54    Vaginal discharge   2016/05                                  F     33         VYRG00000000
  GCH55    Vaginal discharge   2016/10                                  F     33         VYRH00000000
  GCH56    Vaginal discharge   2017/01                                  F     22         VYRI00000000
  GCH57    Vaginal discharge   2017/01                                  F     33         VYRJ00000000
  GCH58    Vaginal discharge   2017/02                                  F     37         VYRK00000000
  GCH59    Vaginal discharge   2017/04                                  F     39         VYRL00000000
  GCH60    Vaginal discharge   2017/07                                  F     33         VYRM00000000
  GCH61    Urine               2010/03                                  M     51         VYRN00000000
  GCH62    Vaginal discharge   2010/03                                  F     38         VYRO00000000
  GCH63    Urine               2010/04                                  M     44         VYRP00000000
  GCH64    Urine               2010/10                                  F     83         VYRQ00000000
  GCH65    Urine               2010/12                                  F     49         VYRR00000000
  GCH66    Vaginal discharge   2010/12                                  F     42         VYRS00000000
  GCH67    Urine               2011/08                                  F     55         VYRT00000000
  GCH68    CSF                 2011/04                                  M     0          VYRU00000000
  GCH70    CSF                 2012/01                                  F     0          VYRW00000000
  GCH71    CSF                 2012/03                                  M     0          VYRX00000000
  GCH72    CSF                 2012/08                                  F     0          VYRY00000000
  GCH73    Vaginal discharge   2014/07                                  F     33         WHUM00000000
  GCH74    Vaginal discharge   2014/08                                  F     40         WHUN00000000
  GCH75    Vaginal discharge   2016/02                                  F     25         WHUO00000000
  GCH76    Urine               2015/11                                  F     79         WHUP00000000
  GCH77    Urine               2016/02                                  M     60         WHUQ00000000
  GCH78    Urine               2014/10                                  M     0          WHUR00000000

Abbreviations: CSF, cerebrospinal fluid; M, male; F, female.

###### 

Phenotypic and genotypic features of *S. agalactiae* for AMR, CPS, ST, and virulence

  Isolate   Antimicrobial susceptibility pattern   Macrolide/lincosamide resistance gene                                                      Tetracycline resistance gene   Aminoglycoside resistance gene                                                                                                                                     ST      CPS genotype   Virulence gene profile
  --------- -------------------------------------- ------------------------------------------------------------------------------------------ ------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------- -------------- ----------------------------------------------------------------------
  GCH2      CRER                                   *erm*(B), *lnu*(B), *lsa*(E), *mre*(A)                                                     *tet*(O)                       *ant*(6)-Ia, *ant*(6)-Ia, *aph*(3′)-III                                                                                                                            12      Ib             *bca-bac[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}-lmb-cylE*
  GCH4      CSES                                   *mre*(A)                                                                                                                                                                                                                                                                                     2       VIII           *rib-lmb-cylE*
  GCH5      CSES                                   *mre*(A)                                                                                                                                                                                                                                                                                     2       VIII           *rib-lmb-cylE*
  GCH7      CSES                                   *mre*(A)                                                                                                                                                                                                                                                                                     2       VIII           *rib-lmb-cylE*
  GCH8      CSES                                   *mre*(A)                                                                                                                                                                                                                                                                                     654     Ib             *bca-bac[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}-lmb-cylE*
  GCH9      CRER                                   *erm*(A), *mre*(A)                                                                         *tet*(M)                                                                                                                                                                                          335     III            *rib-lmb-cylE*
  GCH10     CIES                                   *mre*(A)                                                                                   *tet*(M)                                                                                                                                                                                          23      Ia             *lmb-cylE*
  GCH11     CSES                                   *mre*(A)                                                                                   *tet*(M)                                                                                                                                                                                          23      Ia             *lmb-cylE*
  GCH13     CSES                                   *mre*(A)                                                                                                                                                                                                                                                                                     1,371   VIII           *rib-lmb-cylE*
  GCH14     CRER                                   *erm*(A), *mre*(A)                                                                         *tet*(M)                                                                                                                                                                                          335     III            *rib-lmb-cylE*
  GCH15     CSES                                   *mre*(A)                                                                                                                                                                                                                                                                                     2       VIII           *rib-cylE*
  GCH16     CSES                                   *erm*(B)[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *lnu(*B), *lsa*(E), *mre*(A)   *tet*(M)                       *aac*(6′)-*aph*(2″), *ant*(6)-Ia[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *aph*(3′)-III                                                                  19      III            *rib-lmb-cylE*
  GCH18     CSES                                   *lsa*(C), *mre*(A)                                                                         *tet*(M)                                                                                                                                                                                          23      Ia             *lmb-cylE*
  GCH19     CREI                                   *erm*(B)[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *lnu*(B), *lsa*(E), *mre*(A)   *tet*(M)                       *aac*(6′)-*aph*(2″), *ant*(6)-Ia[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *aph*(3′)-III                                                                  19      III            *rib-lmb-cylE*
  GCH21     CREI                                   *lsa*(C), *mre*(A)                                                                         *tet*(M)                                                                                                                                                                                          23      Ia             *lmb-cylE*
  GCH22     CSES                                   *mre*(A)                                                                                                                                                                                                                                                                                     88      II             *lmb-cylE*
  GCH25     CSES                                   *mre*(A)                                                                                                                                                                                                                                                                                     1       VI             *bca-lmb-cylE*
  GCH26     CSES                                   *mre*(A)                                                                                   *tet*(O)                                                                                                                                                                                          2       VIII           *rib-lmb-cylE*
  GCH28     CSES                                   *mre*(A)                                                                                   *tet*(M)                                                                                                                                                                                          19      III            *rib-lmb-cylE*
  GCH29     CSES                                   *mre*(A)                                                                                                                                                                                                                                                                                     2       VIII           *rib-lmb-cylE*
  GCH30     CRER                                   *erm*(B), *mre*(A)                                                                         *tet*(M)                                                                                                                                                                                          1       V              *lmb-cylE*
  GCH32     CSES                                   *mre*(A)                                                                                                                                                                                                                                                                                     2       VIII           *rib-lmb-cylE*
  GCH33     CRER                                   *erm*(A), *mre*(A)                                                                         *tet*(M)                                                                                                                                                                                          335     III            *rib-lmb-cylE*
  GCH34     CSES                                   *mre*(A)                                                                                   *tet*(M)                                                                                                                                                                                          24      Ia             *bca-lmb-cylE*
  GCH35     CSES                                   *mre*(A)                                                                                                                                                                                                                                                                                     10      Ib             *bca-bac[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}-lmb-cylE*
  GCH36     CSES                                   *mre*(A)                                                                                                                                                                                                                                                                                     10      Ib             *bca-bac[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}-lmb-cylE*
  GCH37     NA                                     *mre*(A)                                                                                                                                                                                                                                                                                     88      Ia             *lmb-cylE*
  GCH38     CREI                                   *erm*(B)[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *lnu*(B), *lsa*(E), *mre*(A)   *tet*(M)                       *aac*(6′)-*aph*(2″), *ant*(6)-Ia[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *aph*(3′)-III                                                                  1,369   III            *bca-lmb-cylE*
  GCH39     CSES                                   *mre*(A)                                                                                   *tet*(M)                                                                                                                                                                                          17      III            *rib-cylE*
  GCH40     CRER                                   *erm*(A), *mre*(A)                                                                         *tet*(M)                                                                                                                                                                                          335     III            *rib-lmb-cylE*
  GCH41     CRER                                   *erm*(B), *mre*(A)                                                                         *tet*(O)                       *ant*(6)-Ia, *ant*(6)-Ia, *aph*(3′)-III                                                                                                                            17      III            *rib-cylE*
  GCH42     CSES                                   *mre*(A)                                                                                                                                                                                                                                                                                     2       VIII           *rib-cylE*
  GCH43     CREI                                   *lnu*(B), *lsa*(E), *mre*(A)                                                               *tet*(M)                       *aac*(6′)-*aph*(2″), *ant*(6)-Ia[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *ant*(6)-Ia, *aph*(3′)-III                                                     19      III            *rib-lmb-cylE*
  GCH44     CSEI                                   *mre*(A)                                                                                                                                                                                                                                                                                     2       VIII           *rib-lmb-cylE*
  GCH45     CSER                                   *mre*(A)                                                                                                                                                                                                                                                                                     2       VIII           *rib-lmb-cylE*
  GCH46     CSES                                   *mre*(A)                                                                                                                                                                                                                                                                                     654     Ib             *bca-bac[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}-lmb-cylE*
  GCH47     CRER                                   *erm*(A), *lnu*(B), *lsa*(E), *mre*(A)                                                     *tet*(M)                       *aac*(6′)-*aph*(2″), *ant*(6)-Ia[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *aph*(3′)-III                                                                  19      V              *cylE*
  GCH48     CRER                                   *erm*(A), *mre*(A)                                                                         *tet*(M)                                                                                                                                                                                          1       V              *lmb-cylE*
  GCH49     CRER                                   *lsa*(C), *mef*(A), *mre*(A), *msr*(D)                                                     *tet*(O)                                                                                                                                                                                          861     III            *rib-lmb-cylE*
  GCH50     CREI                                   *erm*(B)[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *lnu*(B), *lsa*(E), *mre*(A)   *tet*(M)                       *aac*(6′)-*aph*(2″), *ant*(6)-Ia[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *ant*(6)-Ia, *aph*(3′)-III                                                     19      III            *rib-lmb-cylE*
  GCH51     CRER                                   *erm*(B), *mre*(A)                                                                                                                                                                                                                                                                           10      Ib             *bca-bac[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}-lmb-cylE*
  GCH53     CSES                                   *mre*(A)                                                                                   *tet*(M)                                                                                                                                                                                          1       II             *lmb-cylE*
  GCH54     CSES                                   *mre*(A)                                                                                                                                                                                                                                                                                     10      Ib             *bca-bac[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}-lmb-cylE*
  GCH55     CREI                                   *erm*(B)[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *lnu*(B), *lsa*(E), *mre*(A)   *tet*(M)                       *aac*(6′)-*aph*(2″), *ant*(6)-Ia[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *ant*(6)-Ia, *aph*(3′)-III                                                     19      III            *rib-lmb-cylE*
  GCH56     CSES                                   *mre*(A)                                                                                                                                                                                                                                                                                     2       VIII           *rib-lmb-cylE*
  GCH57     CRER                                   *mre*(A)                                                                                                                                                                                                                                                                                     654     Ib             *bca-bac[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}-lmb-cylE*
  GCH58     CREI                                   *erm*(B)[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *lnu*(B), *lsa*(E), *mre*(A)   *tet*(M)                       *aac*(6′)-*aph*(2″), *ant*(6)-Ia[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *aph*(3′)-III                                                                  19      III            *rib-lmb-cylE*
  GCH59     CRER                                   *erm*(A), *mre*(A)                                                                         *tet*(M)                                                                                                                                                                                          335     III            *rib-lmb-cylE*
  GCH60     CSES                                   *mre*(A)                                                                                   *tet*(M)                                                                                                                                                                                          19      III            *rib-lmb-cylE*
  GCH61     CRES                                   *erm*(B)[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *lnu*(B), *lsa*(E), *mre*(A)   *tet*(M)                       *aac*(6′)-*aph*(2″), *ant*(6)-Ia[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *aph*(3′)-III                                                                  19      III            *rib-lmb-cylE*
  GCH62     CRES                                   *lnu*(B), *lsa*(E), *mre*(A)                                                               *tet*(M)                       *aac*(6′)-*aph*(2″), *ant*(6)-Ia[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *ant*(6)-Ia[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *aph*(3′)-III   19      III            *rib-lmb-cylE*
  GCH63     CRES                                   *erm*(B)[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *lnu*(B), *lsa*(E), *mre*(A)   *tet*(M)                       *aac*(6′)-*aph*(2″), *ant*(6)-Ia[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *ant*(6)-Ia, *aph*(3′)-III                                                     19      III            *rib-lmb-cylE*
  GCH64     CRES                                   *erm*(B)[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *lnu*(B), *lsa*(E), *mre*(A)   *tet*(M)                       *aac*(6′)-*aph*(2″), *ant*(6)-Ia[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *aph*(3′)-III                                                                  19      III            *rib-lmb-cylE*
  GCH65     CRES                                   *erm*(B)[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *lnu*(B), *lsa*(E), *mre*(A)   *tet*(M)                       *aac*(6′)-*aph*(2″), *ant*(6)-Ia[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *aph*(3′)-III                                                                  19      III            *rib-lmb-cylE*
  GCH66     CRES                                   *lnu*(B), *lsa*(E), *mre*(A)                                                               *tet*(M)                       *aac*(6′)-*aph*(2″), *ant*(6)-Ia[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *aph*(3′)-III                                                                  19      III            *rib-lmb-cylE*
  GCH67     CRES                                   *erm*(B)[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *lnu*(B), *lsa*(E), *mre*(A)   *tet*(M)                       *aac*(6′)-*aph*(2″), *ant*(6)-Ia[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *aph*(3′)-III                                                                  19      III            *rib-lmb-cylE*
  GCH68     CSES                                   *erm*(A), *mre*(A)                                                                         *tet*(M)                                                                                                                                                                                          335     III            *rib-lmb-cylE*
  GCH70     CSES                                   *erm*(A), *mre*(A)                                                                         *tet*(M)                                                                                                                                                                                          335     III            *rib-lmb-cylE*
  GCH71     CSES                                   *mre*(A)                                                                                   *tet*(M)                                                                                                                                                                                          23      Ia             *lmb-cylE*
  GCH72     CSES                                   *erm*(B)[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *mre*(A)                       *tet*(M)                       *aac*(6′)-*aph*(2″), *ant*(6)-Ia[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *aph*(3′)-III                                                                  19      III            *rib-lmb-cylE*
  GCH73     CSER                                   *mre*(A)                                                                                                                                                                                                                                                                                     1       VI             *bca-lmb-cylE*
  GCH74     CSER                                   *mre*(A)                                                                                   *tet*(M)                                                                                                                                                                                          19      III            *rib-lmb-cylE*
  GCH75     CSER                                   *mef*(A), *mre*(A), *msr*(D)                                                               *tet*(M)                                                                                                                                                                                          23      Ia             *lmb-cylE*
  GCH76     CSER                                   *erm*(A), *mre*(A)                                                                         *tet*(M)                                                                                                                                                                                          19      V              *lmb-cylE*
  GCH77     CSER                                   *mef*(A), *mre*(A), *msr*(D)                                                               *tet*(M)                                                                                                                                                                                          23      Ia             *lmb-cylE*
  GCH78     CSER                                   *erm*(B)[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *mef*(A), *mre*(A), *msr*(D)   *tet*(M)                       *ant*(6)-Ia[\*](#tfn2-alm-2020-40-5-370){ref-type="table-fn"}, *aph*(3′)-III                                                                                       19      III            *rib-lmb-cylE*

Identical nucleotide length\<100% of the reference sequence in the database.

Abbreviations: AMR, antimicrobial resistance; CPS, capsular polysaccharide; CRER, clindamycin-resistant erythromycin-resistant; CSES, clindamycin-susceptible erythromycin-susceptible; CIES, clindamycin-intermediate erythromycin-susceptible; CREI, clindamycin-resistant erythromycin-intermediate; CSEI, clindamycin-susceptible erythromycin-intermediate; CSER, clindamycin-susceptible erythromycin-resistant; CRES, clindamycin-resistant erythromycin-susceptible; ST, sequence type.
